eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 14
Original paper

Silent ischemic brain lesions detected by multi-slice computed tomography are associated with subclinical atrial fibrillation in patients with cardiac resynchronization therapy with subclinical atrial fibrillation in patients with cardiac resynchronization therapy

Yahya Kemal İçen, Ayse Selcan Koc

Adv Interv Cardiol 2018; 14, 3 (53): 285–290
Online publish date: 2018/09/21
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
There is insufficient research on the relationship between subclinical atrial fibrillation (SCAF) and silent ischemic brain lesions (IBLs).

To investigate the relationship between SCAF and silent IBLs in patients with cardiac resynchronization therapy (CRT).

Material and methods
Of 720 CRT implanted patients in our department between 2012 and 2018, 121 patients who underwent elective cranial multi-slice computed tomography (MSCT) during their follow-up were included in our study. Atrial high-rate episodes (AHRE) were detected by the CRT device. Subclinical atrial fibrillation was defined as asymptomatic AHRE longer than 6 min and shorter than 24 h. A cranial MSCT scan was performed using a 128-section scanner with contiguous 2–5 mm axial images. Patients were divided into two groups – with and without silent IBL.

Silent IBLs were detected in 21 (17.4%) of 121 patients with CRT. Ischemic brain lesion presence was found to be associated with age, CHA2DS2-VASc score, left ventricular (LV) ejection fraction (EF), hypertension and SCAF in univariate analysis (p < 0.05). In multivariate regression analysis, presence of SCAF and LVEF were found to be independent parameters predicting the risk of silent IBLs. According to this analysis, the presence of SCAF and every 1% decrease in LVEF were found to increase the risk of silent IBL by 3.5 times and 14.8%, respectively.

Subclinical atrial fibrillation is independently associated with silent IBL presence. Patients with CRT should be closely monitored for SCAF. Patients diagnosed with SCAF should be evaluated for IBL development and treated with the appropriate oral anticoagulant.


cardiac resynchronization therapy, brain ischemia, atrial fibrillation

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962.
Shanmugam N, Boerdlein A, Proff J, et al. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace 2012; 14: 230-7.
Witt CT, Kronborg MB, Nohr EA, et al. Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy. Heart Rhythm 2015; 12: 2368-75.
Sade LE, Atar I, Özin B, et al. Determinants of new-onset atrial fibrillation in patients receiving CRT: mechanistic insights from speckle tracking imaging. JACC Cardiovasc Imaging 2016; 9: 99-111.
Benezet-Mazuecos J, Rubio JM, Iglesias JA, et al. Silent ischaemic brain lesions related to atrial high rate episodes in patients with cardiac implantable electronic devices. Europace 2015; 17: 364-9.
Santini M, Gasparini M, Landolina M, et al.; Cardiological centers participating in ClinicalService Project. Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. J Am Coll Cardiol 2011; 57: 167-72.
Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
Indik JH, Gimbel JR, Abe H, et al. 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. Heart Rhythm 2017; 14: e97-153.
Gorenek B, Bax J, Boriani G, et al. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management – an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardıaca y Electrofisiologıa (SOLEACE). Europace 2017; 0: 1–23.
Defaye P, Dournaux F, Mouton E. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance. Pacing Clin Electrophysiol 1998; 21: 250-5.
Gillis AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. J Cardiovasc Electrophysiol 2002; 13: 542-7.
Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014; 35: 508-16.
Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-53.
Fung JW, Yu CM, Chan JY, et al. Effects of cardiac resynchronization therapy on incidence of atrial fibrillation in patients with poor left ventricular systolic function. Am J Cardiol 2005; 96: 728-31.
Hoppe UC, Casares JM, Eiskjaer H, et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006; 114: 18-25.
Brambatti M, Connolly SJ, Gold MR, et al. ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014; 129: 2094-9.
Borleffs CJ, Ypenburg C, van Bommel RJ, et al. Clinical importance of new-onset atrial fibrillation after cardiac resynchronization therapy. Heart Rhythm 2009; 6: 305-10.
Leclercq C, Padeletti L, Cihak R, et al. Incidence of paroxysmal atrial tachycardias in patients treated with cardiac resynchronization therapy and continuously monitored by device diagnostics. Europace 2010; 12: 71-7.
Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009; 2: 474-80.
Petersen P, Madsen EB, Brun B, et al. Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987; 18: 1098-100.
Feinberg WN, Seeger JF, Carmody RF, Anderson DC, Hart RG, Pearce LA. Asymptomatic cerebral infarction in patients with atrial fibrillation. Circulation 1988; 19: 955-7.
Lin HJ, Wolf PA, Benjamin EJ, et al. Newly diagnosed atrial fibrillation and acute stroke: the Framingham Study. Stroke 1995; 26: 1527-30.
Ezekowitz MD, James KE, Nazarian SM, et al. Silent cerebral infarction in patients with non rheumatic atrial fibrillation. Circulation 1995; 92: 2178-82.
Marfella R, Sasso FC, Siniscalchi M, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol 2013; 62: 525-30.
NCT01938248. Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA); https://clinicaltrials.gov/ct2/show/NCT01938248 (23 October 2015, date last accessed).
https://clinicaltrials.gov/ct2/show/NCT02618577. Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial High Rate Episodes (NOAH). https:// clinicaltrialsgov/ct2/show/NCT02618577 (22 December 2015, date last accessed).
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe